Dinitrophenyl-modified tumor-associated antigens presented on major histocompatibility complex (DNP-TAA/MHC)

Dinitrophenyl-modified tumor-associated antigens (DNP-TAA) presented on major histocompatibility complex (MHC) molecules are the functional targets of hapten-based immunotherapy, specifically autologous tumor cell vaccines [1]. By chemically conjugating the dinitrophenyl (DNP) hapten to tumor cells, the immune system is forced to recognize tumor-associated antigens that were previously ignored due to self-tolerance [2]. These DNP-modified antigens are processed by antigen-presenting cells and presented on MHC Class I and II molecules to activate CD8+ cytotoxic T-lymphocytes and CD4+ helper T-lymphocytes [3]. The activation of CD4+ cells by the DNP-hapten provides the necessary help to generate a robust and sustained CD8+ T-cell response against the native, unmodified tumor antigens [1,4]. This approach has been extensively studied in clinical trials for metastatic melanoma and ovarian cancer, demonstrating the induction of delayed-type hypersensitivity (DTH) and infiltration of T-cells into metastatic sites [1,2]. The therapeutic goal is to transform the tumor into an immunogenic target, leading to systemic anti-tumor immunity [3,4]. Sources: [1] Berd D, et al. J Clin Oncol. 1997;15(6):2359-70; [2] Berd D, et al. Cancer Res. 1991;51(10):2731-4; [3] Manne J, et al. Cancer Res. 2002;62(21):6090-7; [4] Soiffer R, et al. Proc Natl Acad Sci U S A. 1998;95(22):13141-6.

Other names

DNP-modified autologous tumor cellsHapten-modified tumor antigensDNP-conjugated tumor-associated antigensDNP-TAADNP-modified MHC-peptide complexes

Haptenization of tumor-associated antigens with dinitrophenyl (DNP) to enhance immunogenicity and bypass self-tolerance, leading to the activation of CD4+ helper and CD8+ cytotoxic T-lymphocytes against both modified and native tumor cells.